Replies to post #184527 on Biotech Values

[jq1234]

ARIA: I guess nothing was learned. Perfect example of how a dysfunctional biotech company taking excessive risk and potentially wasting money in the process. Run a large dose ranging trial at the same time as a large randomized trial in earlier line? If you don't know what's the best dosing regimen is, how could you run a large randomized trial for early line at the same time?

Three new Iclusig clinical trials are planned to begin in 2015, two of which will evaluate Iclusig in earlier lines of treatment, as follows:

A randomized, Phase 3 trial in approximately 500 patients with chronic-phase chronic myeloid leukemia (CP-CML) who have experienced treatment failure after imatinib therapy.

A dose-ranging trial of Iclusig in approximately 450 patients with CP-CML who have become resistant to at least two prior TKIs.

An early-switch trial of Iclusig in approximately 1,000 patients with CP-CML in the United Kingdom (known as the SPIRIT3 trial) - an investigator-sponsored trial (IST).

http://investor.ariad.com/mobile.view?c=118422&v=203&d=1&id=2018104